Clinical review report Riociguat (Adempas)
The objective of this systematic review is to evaluate the beneficial and harmful effects of riociguat 0.5 mg, 1 mg, 1.5 mg, 2 mg, and 2.5 mg tablets for the treatment of pulmonary arterial hypertension in adults (World Health Organization [WHO] functional class II or III).
| Autor principal: | |
|---|---|
| Autor Corporativo: | |
| Formato: | Libro electrónico |
| Idioma: | Inglés |
| Publicado: |
Ottawa, Ontario :
Canadian Agency for Drugs and Technologies in Health
2015.
|
| Materias: | |
| Ver en Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820282006719 |
| Sumario: | The objective of this systematic review is to evaluate the beneficial and harmful effects of riociguat 0.5 mg, 1 mg, 1.5 mg, 2 mg, and 2.5 mg tablets for the treatment of pulmonary arterial hypertension in adults (World Health Organization [WHO] functional class II or III). |
|---|---|
| Descripción Física: | 1 online resource (1 PDF file (74 pages)) : illustrations |
